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Knowledge management is positioned as an enabler of ICH Q10, and the visibility and availability of 
product and process knowledge across the entire pharmaceutical product lifecycle is vital to the 
sustained success of an organization and to the effectiveness of an organization’s pharmaceutical 
quality system as defined by ICH Q10.  This paper illustrates where knowledge management has a role 
to play within each product lifecycle phase.  This paper goes on to further define phase-appropriate 
KM methods and tools to help address these needs and create end-to-end product and process 




Developing and manufacturing medicines is a deeply scientific endeavor, and an organization’s ability 
to find, apply and grow knowledge is fundamental to its sustained success.  When considering the 
purpose of knowledge management (KM) in the biopharmaceutical industry, the goal should be to 
prospectively manage knowledge as an asset so that the best possible knowledge is available when 
and where it is needed to enable patient optimal outcomes.  Knowledge management can support 
this ambition through enabling a highly effective pharmaceutical quality system, inclusive of risk-
based decision making powered by knowledge.  Knowledge management indeed is positioned as an 
enabler to the pharmaceutical quality system as established in ICH Q10 [1].  The Pharmaceutical 
Product Knowledge Lifecycle (PPKL) Model [2] highlights this by identifying the need for product and 




Figure 1:  The Pharmaceutical Product Knowledge Lifecycle (PPKL) Model [2] 
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The need for KM during each phase of the pharmaceutical product lifecycle 
 
To accomplish this, there are a variety of effective KM methods and tools1 available to manage 
knowledge across the pharmaceutical product lifecycle [3].  Understanding the key focus of each 
lifecycle phase provides an opportunity to select phase-appropriate KM methods and tools.  The intent 
is not to create ‘silos’ by having distinct KM methods and tools per phase, but rather to understand 
the end-to-end needs to manage knowledge and to deploy relevant, fit-for-purpose KM methods and 
tools embedded in the flow of work.  A best-practice principle to enable effective knowledge 
management is to deploy standardized KM methods and tools [3].  With standardized approaches and 
thoughtful consideration of the end-to-end needs, knowledge can be managed in a very intentional, 
consistent and visible manner across the product lifecycle and across products.  This improved visibility 
and availability of product knowledge will better enable the goals of ICH Q10 (i.e., (i) product 
realization, (ii) establishing a state of control and (iii) a basis for continual improvement [1]) and form 
the basis for ‘prior knowledge’ to be available in the future.  
 
Following for each lifecycle phase in sequence is a list of illustrative knowledge-related activities and 





Considering Product Development, illustrative knowledge-related activities include: 
 
• Application of prior knowledge for risk assessments to determine areas of study 
• Development work to capture new knowledge 
• Ongoing risk assessment and risk control 
 
Knowledge Management should be a key enabler to Product Development through standardized 
methods and tools delivering the following:   
 
• Access to prior knowledge (platform technologies, other products, expertise in the company 
(individuals & CoEs2), external scientific literature, prior learnings & lessons, et al.) 
• Capture of new knowledge during early development work (both what worked and what did 
not) 
• The record of product development, including scientific knowledge and supporting design 
choices and other decision rationale 
 
 
New Product Introduction / Technology Transfer 
 
Considering New Product Introduction / Technology Transfer, illustrative knowledge-related activities 
include: 
 
• Application of knowledge for risk assessments 
• Comprehensive knowledge transfer 
• Opportunity to learn more about the product/process 
 
1 Methods and tools are also commonly referred to as KM practices, approaches or capabilities 
2 CoE = Center of Excellence 
2
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• Supporting the goal to ensure a right-first time transfer, robust process and capable receiving 
site 
 
Knowledge Management should be a key enabler to New Product Introduction / Technology Transfer 
through standardized methods and tools delivering the following:   
 
• Access to comprehensive product and process knowledge, including development and 
manufacturing history, including key decisions, learnings from failures, changes, etc. 
• Access to subject matter experts / personnel with process experience 
• Capture of new learnings including increased knowledge and understanding of 
product/process, lessons learned, etc. 
 
 
Commercial Manufacturing / Continuous Improvement 
 
Considering Commercial Manufacturing / Continuous Improvement, illustrative knowledge-related 
activities include: 
 
• Ongoing knowledge build through accumulated manufacturing experience 
• Lifecycle management, including planned and unplanned changes 
• Seek to minimize disruptions to product availability by rapid problem solving and solving 
problems at root cause 
 
Knowledge Management should be a key enabler to Commercial Manufacturing / Continuous 
Improvement through standardized methods and tools delivering the following:   
 
• Capture of new learnings including increased knowledge and understanding of 
product/process, lessons learned, etc.  
• Knowledge visibility and availability across the full product lifecycle (including development) 
to ensure broad access to knowledge to support process monitoring, continual improvement, 
change management, investigations, et al 
• Support for problem solving and sharing of best practices and improvements across the 





Considering Product Discontinuation, illustrative knowledge-related activities include: 
 
• Knowledge transfer for archival and future access on demand 
• Harvesting learnings to inform 'prior knowledge' 
 
Knowledge Management should be a key enabler to Product Discontinuation through standardized 
methods and tools delivering the following:   
 
• Capture of knowledge in a complete and structured manner to allow for future access (e.g. 
stability, complaints, etc.) 
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Phase-appropriate KM methods & tools 
 
Table 1, Phase-appropriate KM methods & tools across the pharmaceutical product lifecycle, provides 
a summary of the above considerations and corresponding KM methods and tools which can be 
deployed to fulfill the needs of each lifecycle phase.  These methods and tools are organized by those 
required for Planning & Requirements Definition, Mostly Explicit (knowledge)-based methods and 
tools, Mostly Tacit (knowledge)-based methods and tools, and Enabling Elements.   Table 2, Description 
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Table 1:  Phase-appropriate KM methods & tools across the pharmaceutical product lifecycle 
Lifecycle Phase
Areas of emphasis where 
knowledge is required
How Knowledge Management can provide benefit… 
Common KM elements for Product Development  phase X X X X X X
Access to prior knowledge (platform technologies, other 
products, expertise in the company (individuals & CoEs), 
external scientific literature, prior learnings & lessons, et al)
X X X X X X X
Capture of new knowledge during early development work 
(both what worked and what didn't)
X X X X X X X X
The record of product development, including scientific 
knowledge and supporting design choices and other decision 
rationale
X X X X X X X X X
Common KM elements for Technology Transfer  phase X X X X X
Access to comprehensive product and process knowledge, 
including development and manufacturing history, including 
key decisions, learnings from failures, changes, etc.
X X X X X X X X X X X X
Access to subject matter experts / personnel with process 
experience
X X X X X
Capture of new learnings including increased knowledge and 
understanding of product/process, lessons learned, etc.
X X X X X X X X X X
Common KM elements for Commercial Manufacturing  phase X X X X X X
Capture of new learnings including increased knowledge and 
understanding of product/process, lessons learned, etc.
X X X X X X X X X X
Knowledge visibility and availability across the full product 
lifecycle (including development) to ensure broad access to 
knowledge to support process monitoring, continual 
improvement, change management, investigations, et al
X X X X X X X X X X X
Support for problem solving and sharing of best practices and 
improvements across the supply chain and back to 
development organization
X X X X X X X X X X X
Common KM elements for Product Discontinuation  phase X X X X
Capture of knowledge in a complete and structured manner to 
allow for future access (e.g. stability, complaints, etc.)
X X X X X X X X
Capture of learnings including insights for platform knowledge 
and other potential 'prior knowledge'
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Note 1:  Illustrative concepts, not an exhaustive listing
Note 2:  References below to knowledge refer to both  explicit and tacit knowledge




















































































- Application of knowledge for risk 
assessments
- Comprehensive knowledge transfer
- Opportunity to learn more about the 
product/process
- Supporting the goal to ensure a right-






- Ongoing knowledge build through 
accumulated manufacturing experience
- Lifecycle management, including 
planned and unplanned changes
- Seek to minimize disruptions to 
product availability by rapid problem 




- Knowledge transfer for archival and 
future access on demand
- Harvesting learnings to inform 'prior 
knowledge'
KM Methods & Tools
Planning & Requirements 
Definition
Mostly Explicit-based Mostly Tacit-based Enabling elements
Product 
Development
- Application of prior knowledge for risk 
assessments to determine areas of study
- Development work to capture new 
knowledge
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Table 2:  Description of KM Methods and Tools 
 
KM Method or Tool Description  
Planning & Requirements Definition 
KM Maturity Assessment  
A means to objectively measure maturity of KM effectiveness 
based on various attributes such as process, culture, 
technology, etc. 
Knowledge Mapping 
A structured means to document the knowledge needed for a 
business process, a functional group, a role, etc.  Used to 
understand knowledge requirements and identify gaps.  
Product KM Plan 
A strategy document to define the plan for how the 
knowledge associated with a product will be managed. 
Knowledge Transfer Plan 
A strategy document to define the plan for how the 
knowledge transfer will be managed.  
Site / Functional Area KM Plan 
A strategy document to define the plan for how the 




A structured3 means to manage documents and other explicit 
knowledge (e.g., videos, pictures, etc.).  Typically includes the 
end-to-end lifecycle of content (e.g., creation, tagging, 
storage, delivery).  Applies to both GMP and non-GMP content 
which may be managed in separate systems. 
Taxonomy & Search 
Taxonomy is a structured means to describe and tag content 
(and potentially other features such as synonyms, semantics, 
etc.), and a means to deliver results through a robust, 
integrated search enabled by such a taxonomy. 
Platform Knowledge Base 
A structured means to define the scope of platform knowledge 
(explicit and tacit) and corresponding approaches to manage 
this in a consistent way to ensure knowledge visibility and 
availability across the product lifecycle. 
Product Knowledge Base 
A structured means to define the scope of product knowledge 
(explicit and tacit) and corresponding approaches to manage 
this in a consistent way to ensure knowledge visibility and 
availability across the product lifecycle. 
Mostly Tacit-based 
Communities of Practice 
A structured means to connect groups of people with a shared 
need or interest 
After Action Review / Lessons 
Learned 
A structured means to surface learnings from the experiences 
of people, often associated with a project or other business 
process, and subsequently capture and implement these 
learnings to support continual improvement.  
Expertise Location 
A structured means to identify important expertise and/or 
experience in the organization and connect to it on demand.  
Decision Rationale Capture 
A structured means to capture decision rationale and ensure it 
is available in the future when needed. 
 
3 Structured = Standardized and inclusive of people, process, technology and governance 
6
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KM Method or Tool Description  
Tacit Knowledge Retention & 
Transfer Practices 
A variety of structured means to identify, prioritize, transfer 
and retain tacit knowledge (i.e., know-how and other 
knowledge “in people’s heads”) 
Enabling Elements 
KM Roles 
Standardized roles for managing knowledge consistently, such 
as community stewards. 
KM Training 
Training on appropriate KM topics to build awareness and 
competency of individuals in the organization. 
Knowledge-valuing culture 
Mindsets and behaviors which value the knowledge of the 
organization as an asset (e.g., capturing and sharing lessons, 
seeking to leverage prior knowledge) 
Sponsorship, Governance, 
Metrics & Other enablers 




While there is no “one right answer” on how to best manage knowledge across the pharmaceutical 
product lifecycle, a pragmatic approach to understand the intent and focus of each phase can provide 
valuable insights on how knowledge might be utilized and how KM can address these needs.  This 
paper provides a high-level outline to illustrate this, and subsequent effort can be undertaken to 
further define the specific requirements (what processes, what knowledge, what users, etc.).  In fact, 
the Planning & Requirements Definition section provides the impetus to do just this – to leverage such 
approaches to create an intentional plan (e.g., product, site or knowledge transfer plans) supported 
by a clear definition of the knowledge needed (provided by a knowledge map).  The authors hope that 
while this is described at a high-level in this paper, the concepts will be useful to further “demystify” 
what can be done to make progress in knowledge management in support of ICH Q10 and overall 
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